Uremic Pruritus Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline Analysis | Sol-Gel Technologies Ltd., Krystal Biotech Inc.

DelveInsight's, "Uremic Pruritus - Pipeline Insight, 2025" report provides comprehensive insights about 2+ companies and 2+ pipeline drugs in Uremic Pruritus pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
According to DelveInsight, over two key companies are actively engaged in developing more than two treatment therapies for Uremic Pruritus, reflecting ongoing efforts to address this condition.

Uremic Pruritus Overview:

Uremic pruritus (UP), also referred to as chronic kidney disease-associated pruritus (CKD-aP), is a common and burdensome condition seen in individuals with advanced chronic kidney disease, especially those undergoing dialysis. It is marked by ongoing itching, usually without a clear skin-related cause, and can severely impact a patient's quality of life. While the exact cause remains unclear, it is thought to involve systemic inflammation, metabolic disturbances, and the buildup of uremic toxins due to reduced kidney function.

The main symptom is relentless itching, which may be generalized or localized to areas such as the back, arms, or face. Itching tends to worsen at night, leading to sleep disturbances and fatigue. Although the skin often appears normal in the early stages, prolonged scratching can cause visible damage like lesions and thickened skin. UP often coexists with other CKD-related symptoms such as dry skin and muscle cramps.

Diagnosis is based largely on clinical evaluation, considering a patient's history of CKD and persistent itching in the absence of a clear alternative explanation. Physicians typically exclude other possible causes, such as allergic reactions or dermatological diseases, through physical exams and laboratory tests. Although there is no definitive cure, treatment focuses on relieving symptoms and enhancing quality of life. Management strategies include improving dialysis efficiency to lower toxin levels, applying moisturizers for dry skin, and using medications like antihistamines or gabapentinoids to control itching. In more severe cases, systemic therapies such as opioid receptor modulators (e.g., nalfurafine), corticosteroids, and narrowband UVB phototherapy may offer additional relief.

Request for a detailed insights report on Uremic Pruritus pipeline insights @ https://www.delveinsight.com/report-store/uremic-pruritus-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr

"Uremic Pruritus Pipeline Insight 2025" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Uremic Pruritus Therapeutics Market.

Key Takeaways from the Uremic Pruritus Pipeline Report

*
DelveInsight's Uremic Pruritus pipeline report depicts a robust space with 2+ active players working to develop 2+ pipeline therapies for Uremic Pruritus treatment.

*
Key Uremic Pruritus companies such as Qilu Pharmaceutical, and others are evaluating new drugs for Uremic Pruritus to improve the treatment landscape.

*
Promising Uremic Pruritus pipeline therapies in various stages of development include QLG2198, and others.

*
Lumosa Therapeutics is developing LT5001, a topical ointment containing dinalbuphine sebacate (DNS), designed to alleviate pruritus. DNS acts as a kappa-opioid receptor agonist and mu-opioid receptor antagonist, aiming to reduce itching without significant systemic absorption. This formulation offers a convenient application for patients.

*
The U.S. Food and Drug Administration (FDA) approved difelikefalin, marketed as Korsuva, for the treatment of moderate to severe pruritus in adults undergoing hemodialysis. This approval marked the first FDA-endorsed treatment specifically targeting uremic pruritus, offering relief to patients who previously had limited options.

Uremic Pruritus Pipeline Analysis

The report provides insights into:

*
The report provides detailed insights into the key companies that are developing therapies in the Uremic Pruritus Market.

*
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Uremic Pruritus treatment.

*
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

*
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

*
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Uremic Pruritus market.

Download our free sample page report on Uremic Pruritus pipeline insights [https://www.delveinsight.com/sample-request/uremic-pruritus-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Uremic Pruritus Emerging Drugs

*
QLG2198: Qilu Pharmaceutical

Uremic Pruritus Companies

Approximately two or more leading companies are actively developing treatments for uremic pruritus. Among them, Qilu Pharmaceutical has the most advanced drug candidates, currently in Phase III clinical trials.

DelveInsight's report covers around 2+ products under different phases of clinical development like

*
Late stage products (Phase III)

*
Mid-stage products (Phase II)

*
Early-stage product (Phase I) along with the details of

*
Pre-clinical and Discovery stage candidates

*
Discontinued & Inactive candidates

Uremic Pruritus pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

*
Intravenous

*
Subcutaneous

*
Oral

*
Intramuscular

Uremic Pruritus Products have been categorized under various Molecule types such as

*
Monoclonal antibody

*
Small molecule

*
Peptide

Download Sample Pages to Get an in-depth Assessment of the Emerging Uremic Pruritus Therapies and Key Companies: Uremic Pruritus Clinical Trials and advancements [https://www.delveinsight.com/report-store/uremic-pruritus-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Uremic Pruritus Pipeline Therapeutic Assessment

- Uremic Pruritus Assessment by Product Type

- Uremic Pruritus By Stage

- Uremic Pruritus Assessment by Route of Administration

- Uremic Pruritus Assessment by Molecule Type

Download Uremic Pruritus Sample report to know in detail about the Uremic Pruritus treatment market @ Uremic Pruritus Therapeutic Assessment [https://www.delveinsight.com/sample-request/uremic-pruritus-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Table of Content

1. Report Introduction

2. Executive Summary

3. Uremic Pruritus Current Treatment Patterns

4. Uremic Pruritus - DelveInsight's Analytical Perspective

5. Therapeutic Assessment

6. Uremic Pruritus Late-Stage Products (Phase-III)

7. Uremic Pruritus Mid-Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Uremic Pruritus Discontinued Products

13. Uremic Pruritus Product Profiles

14. Uremic Pruritus Key Companies

15. Uremic Pruritus Key Products

16. Dormant and Discontinued Products

17. Uremic Pruritus Unmet Needs

18. Uremic Pruritus Future Perspectives

19. Uremic Pruritus Analyst Review

20. Appendix

21. Report Methodology

Request the Sample PDF to Get Detailed Insights About the Uremic Pruritus Pipeline Reports Offerings [https://www.delveinsight.com/report-store/uremic-pruritus-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=uremic-pruritus-clinical-trials-companies-therapeutic-assessment-therapies-treatment-algorithm-pipeline-analysis-solgel-technologies-ltd-krystal-biotech-inc]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.